Cargando…

Glycaemic control in the paediatric and young adult population with type 1 diabetes following a single telehealth visit - what have we learned from the COVID-19 lockdown?

AIMS: Children with chronic diseases were unable to receive their usual care during COVID-19 lockdown. We assessed the feasibility and impact of telehealth visits on the time-in-range (TIR) of paediatric individuals with type 1 diabetes (T1D). METHODS: An observational multicentre real-life study. P...

Descripción completa

Detalles Bibliográficos
Autores principales: Rachmiel, Marianna, Lebenthal, Yael, Mazor-Aronovitch, Kineret, Brener, Avivit, Levek, Noa, Levran, Neria, Chorna, Efrat, Dekel, Michal, Barash, Galia, Landau, Zohar, Pinhas-Hamiel, Orit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Milan 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7842171/
https://www.ncbi.nlm.nih.gov/pubmed/33511493
http://dx.doi.org/10.1007/s00592-021-01673-2
_version_ 1783643958831742976
author Rachmiel, Marianna
Lebenthal, Yael
Mazor-Aronovitch, Kineret
Brener, Avivit
Levek, Noa
Levran, Neria
Chorna, Efrat
Dekel, Michal
Barash, Galia
Landau, Zohar
Pinhas-Hamiel, Orit
author_facet Rachmiel, Marianna
Lebenthal, Yael
Mazor-Aronovitch, Kineret
Brener, Avivit
Levek, Noa
Levran, Neria
Chorna, Efrat
Dekel, Michal
Barash, Galia
Landau, Zohar
Pinhas-Hamiel, Orit
author_sort Rachmiel, Marianna
collection PubMed
description AIMS: Children with chronic diseases were unable to receive their usual care during COVID-19 lockdown. We assessed the feasibility and impact of telehealth visits on the time-in-range (TIR) of paediatric individuals with type 1 diabetes (T1D). METHODS: An observational multicentre real-life study. Patients scheduled for an in-clinic visit during the lockdown were offered to participate in a telehealth visit. Sociodemographic, clinical, continuous glucose monitor and pump data were recorded 2 weeks prior and 2 weeks after telehealth visit. The primary endpoint was change in relative-TIR, i.e. change in TIR divided by the percent of possible change (∆TIR/(100-TIRbefore)*100). RESULTS: The study group comprised 195 individuals with T1D (47.7% males), mean±SD age 14.6 ± 5.3 years, and diabetes duration 6.0 ± 4.6 years. Telehealth was accomplished with 121 patients and their parents (62.0%); 74 (38.0%) did not transfer complete data. Mean TIR was significantly higher for the two-week period after the telehealth visit than for the two-week period prior the visit (62.9 ± 16.0, p < 0.001 vs. 59.0 ± 17.2); the improvement in relative-TIR was 5.7±26.1%. Initial higher mean glucose level, lower TIR, less time spent at <54 mg/dl range, longer time spent at 180–250 mg/dl range, higher daily insulin dose, and single-parent household were associated with improved relative-TIR. Multiple regression logistic analysis demonstrated only initial lower TIR and single-parent household were significant, odds ratio: −0.506, (95%CI −0.99,−0.023), p=0.04 and 13.82, (95%CI 0.621, 27.016), p=0.04, respectively. CONCLUSIONS: Paediatric and young adult patients with T1D benefited from a telehealth visit during COVID-19. However, this modality is not yet suitable for a considerable proportion of patients.
format Online
Article
Text
id pubmed-7842171
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer Milan
record_format MEDLINE/PubMed
spelling pubmed-78421712021-01-29 Glycaemic control in the paediatric and young adult population with type 1 diabetes following a single telehealth visit - what have we learned from the COVID-19 lockdown? Rachmiel, Marianna Lebenthal, Yael Mazor-Aronovitch, Kineret Brener, Avivit Levek, Noa Levran, Neria Chorna, Efrat Dekel, Michal Barash, Galia Landau, Zohar Pinhas-Hamiel, Orit Acta Diabetol Original Article AIMS: Children with chronic diseases were unable to receive their usual care during COVID-19 lockdown. We assessed the feasibility and impact of telehealth visits on the time-in-range (TIR) of paediatric individuals with type 1 diabetes (T1D). METHODS: An observational multicentre real-life study. Patients scheduled for an in-clinic visit during the lockdown were offered to participate in a telehealth visit. Sociodemographic, clinical, continuous glucose monitor and pump data were recorded 2 weeks prior and 2 weeks after telehealth visit. The primary endpoint was change in relative-TIR, i.e. change in TIR divided by the percent of possible change (∆TIR/(100-TIRbefore)*100). RESULTS: The study group comprised 195 individuals with T1D (47.7% males), mean±SD age 14.6 ± 5.3 years, and diabetes duration 6.0 ± 4.6 years. Telehealth was accomplished with 121 patients and their parents (62.0%); 74 (38.0%) did not transfer complete data. Mean TIR was significantly higher for the two-week period after the telehealth visit than for the two-week period prior the visit (62.9 ± 16.0, p < 0.001 vs. 59.0 ± 17.2); the improvement in relative-TIR was 5.7±26.1%. Initial higher mean glucose level, lower TIR, less time spent at <54 mg/dl range, longer time spent at 180–250 mg/dl range, higher daily insulin dose, and single-parent household were associated with improved relative-TIR. Multiple regression logistic analysis demonstrated only initial lower TIR and single-parent household were significant, odds ratio: −0.506, (95%CI −0.99,−0.023), p=0.04 and 13.82, (95%CI 0.621, 27.016), p=0.04, respectively. CONCLUSIONS: Paediatric and young adult patients with T1D benefited from a telehealth visit during COVID-19. However, this modality is not yet suitable for a considerable proportion of patients. Springer Milan 2021-01-28 2021 /pmc/articles/PMC7842171/ /pubmed/33511493 http://dx.doi.org/10.1007/s00592-021-01673-2 Text en © Springer-Verlag Italia S.r.l., part of Springer Nature 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Original Article
Rachmiel, Marianna
Lebenthal, Yael
Mazor-Aronovitch, Kineret
Brener, Avivit
Levek, Noa
Levran, Neria
Chorna, Efrat
Dekel, Michal
Barash, Galia
Landau, Zohar
Pinhas-Hamiel, Orit
Glycaemic control in the paediatric and young adult population with type 1 diabetes following a single telehealth visit - what have we learned from the COVID-19 lockdown?
title Glycaemic control in the paediatric and young adult population with type 1 diabetes following a single telehealth visit - what have we learned from the COVID-19 lockdown?
title_full Glycaemic control in the paediatric and young adult population with type 1 diabetes following a single telehealth visit - what have we learned from the COVID-19 lockdown?
title_fullStr Glycaemic control in the paediatric and young adult population with type 1 diabetes following a single telehealth visit - what have we learned from the COVID-19 lockdown?
title_full_unstemmed Glycaemic control in the paediatric and young adult population with type 1 diabetes following a single telehealth visit - what have we learned from the COVID-19 lockdown?
title_short Glycaemic control in the paediatric and young adult population with type 1 diabetes following a single telehealth visit - what have we learned from the COVID-19 lockdown?
title_sort glycaemic control in the paediatric and young adult population with type 1 diabetes following a single telehealth visit - what have we learned from the covid-19 lockdown?
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7842171/
https://www.ncbi.nlm.nih.gov/pubmed/33511493
http://dx.doi.org/10.1007/s00592-021-01673-2
work_keys_str_mv AT rachmielmarianna glycaemiccontrolinthepaediatricandyoungadultpopulationwithtype1diabetesfollowingasingletelehealthvisitwhathavewelearnedfromthecovid19lockdown
AT lebenthalyael glycaemiccontrolinthepaediatricandyoungadultpopulationwithtype1diabetesfollowingasingletelehealthvisitwhathavewelearnedfromthecovid19lockdown
AT mazoraronovitchkineret glycaemiccontrolinthepaediatricandyoungadultpopulationwithtype1diabetesfollowingasingletelehealthvisitwhathavewelearnedfromthecovid19lockdown
AT breneravivit glycaemiccontrolinthepaediatricandyoungadultpopulationwithtype1diabetesfollowingasingletelehealthvisitwhathavewelearnedfromthecovid19lockdown
AT leveknoa glycaemiccontrolinthepaediatricandyoungadultpopulationwithtype1diabetesfollowingasingletelehealthvisitwhathavewelearnedfromthecovid19lockdown
AT levranneria glycaemiccontrolinthepaediatricandyoungadultpopulationwithtype1diabetesfollowingasingletelehealthvisitwhathavewelearnedfromthecovid19lockdown
AT chornaefrat glycaemiccontrolinthepaediatricandyoungadultpopulationwithtype1diabetesfollowingasingletelehealthvisitwhathavewelearnedfromthecovid19lockdown
AT dekelmichal glycaemiccontrolinthepaediatricandyoungadultpopulationwithtype1diabetesfollowingasingletelehealthvisitwhathavewelearnedfromthecovid19lockdown
AT barashgalia glycaemiccontrolinthepaediatricandyoungadultpopulationwithtype1diabetesfollowingasingletelehealthvisitwhathavewelearnedfromthecovid19lockdown
AT landauzohar glycaemiccontrolinthepaediatricandyoungadultpopulationwithtype1diabetesfollowingasingletelehealthvisitwhathavewelearnedfromthecovid19lockdown
AT pinhashamielorit glycaemiccontrolinthepaediatricandyoungadultpopulationwithtype1diabetesfollowingasingletelehealthvisitwhathavewelearnedfromthecovid19lockdown